ACE OncoCast
The official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.
ACE OncoCast
The Role of Immunotherapy in LA SCCHN
•
ACE Oncology
•
Season 3
•
Episode 2
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Based on improved survival, PD-1 immune checkpoint inhibitors (± chemotherapy) have become the standard of care for patients with recurrent/metastatic SCCHN. However, in patients with locally advanced disease, the results of several clinical trials evaluating the addition of PD-(L)1 inhibitors to conventional chemoradiotherapy have been disappointing. Dr. Ezra Cohen, Dr. Yungan Tao, and Dr. Jonathan Schoenfeld discuss the potential reasons for immunotherapy failure, promising neoadjuvant immunotherapy approaches, and some ongoing, eagerly awaited trials that will hopefully help to define the role of immunotherapy in LA SCCHN.